Blog

14 Jul The 2026 State of 340B Compliance: What’s Working, What Isn’t, and Where the Gaps Are Widening

Posted at 2:28 AM in Blog by Scott Ponaman

340B compliance in 2026 demands more than enrollment and policy documentation. Covered entities must maintain real-time oversight of patient eligibility, contract pharmacy arrangements, and audit-ready documentation. All under intensified HRSA scrutiny. Organizations treating compliance as a periodic exercise rather than a continuous operational function are...

07 Jul When to Act and When to Wait: Timing Decisions in 340B Compliance That Determine Audit Outcomes

Posted at 2:21 AM in Blog by Scott Ponaman

Timing in 340B compliance isn't about how fast you move. It's about whether you're moving on the right issue at the right moment. Programs that overreact to every regulatory update exhaust their teams on non-issues. Programs that delay on known internal gaps hand HRSA the...

29 Jun When Your 340B Consultant Is the Risk: Warning Signs, Red Flags, and What Credible Guidance Actually Looks Like

Posted at 5:06 AM in Blog by Scott Ponaman

The 340B program is one of the most scrutinized federal drug pricing programs in existence — and the consultants who claim to simplify it can sometimes create more exposure than they prevent. Compliance officers and program managers working inside real healthcare organizations know this tension...

23 Jun How Ponaman Healthcare Consulting Approaches HRSA 340B Program Compliance: The Methodology Behind the Results

Posted at 4:57 AM in Blog by Scott Ponaman

The 340B drug pricing program saves eligible healthcare organizations hundreds of millions of dollars annually — but according to HRSA's own audit data, a significant portion of covered entities struggle to maintain the documentation standards required to keep those savings. For compliance officers and program...

13 Jun What Real ROI From 340B Consulting Looks Like — And What Drives the Difference

Posted at 4:45 AM in Blog by Scott Ponaman

The 340B drug pricing program can reduce covered entity drug costs by 25–50% compared to market rates, according to HRSA program data — but practitioners consistently report that the gap between organizations capturing that value and those leaving it on the table comes down to...

05 Jun 340B Consulting vs. the Alternatives: An Honest Tradeoff Analysis for Compliance-Focused Organizations

Posted at 4:31 AM in Blog by Scott Ponaman

Managing a 340B program without dedicated expertise is like navigating federal audit requirements using the regulation text alone — technically possible, practically costly. HRSA's Office of Pharmacy Affairs has steadily increased audit activity over the past several years, and the consequences of an audit finding...

28 May 340B Program Eligibility: Who Qualifies and How to Apply to Access Federal Medication Savings

Posted at 4:20 AM in Blog by Scott Ponaman

The 340B Drug Pricing Program is a federal initiative that lets eligible healthcare providers—known as covered entities—buy certain medications at discounted prices. Knowing the eligibility requirements and the registration steps is critical for organizations that want to capture these savings and reinvest them in patient...

22 May What Is the 340B Program? A Complete Guide to Eligibility, Compliance, and Benefits for Covered Entities

Posted at 4:01 AM in Blog by Scott Ponaman

The 340B Drug Pricing Program is a federal policy aimed at helping safety-net providers stretch their budgets so they can serve more patients in need. By allowing eligible organizations to buy outpatient medicines at reduced prices, the program frees up funds that can be reinvested...

16 May 340B Contract Pharmacy: Benefits, Risks, and Best Practices for Compliance and Optimization

Posted at 3:49 AM in Blog by Scott Ponaman

The 340B contract pharmacy program is a core tool in the U.S. safety-net: it lets eligible providers secure discounted outpatient drugs so they can stretch limited resources and serve more patients. This guide breaks down how the program works, the concrete advantages it offers, the...

07 May How Covered Entities Stay 340B Compliant: Essential Rules and Practical Best Practices

Posted at 3:41 AM in Blog by Scott Ponaman

Maintaining 340B compliance is critical for covered entities that rely on the program to deliver affordable medications to vulnerable patients. This guide lays out the core requirements, ongoing responsibilities, and practical steps organizations should take to manage 340B risk. You’ll find clear guidance on eligibility,...